New research from industry analyst Research and Markets highlights the potential of the bispecific antibody market, indicating strong growth in the present period.
Leveraging advances in medical research, this type of antibody works by using the immune system to target malignant and other diseased cells and tissues with precision.
Currently, there are over 800 candidates of this kind in clinical development, with late stage trials underway across a range of solid cancers like triple negative breast cancer, small cell lung cancer and bladder cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze